Candel Therapeutics (CADL) Appoints Maha Radhakrishnan to its Board

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. SMCI
8. RTX
9. S
10. COF

Go back to Candel Therapeutics (CADL) Appoints Maha Radhakrishnan to its Board

Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

June 6, 2025 8:05 AM EDT

Appointment of seasoned strategic industry executive strengthens the Board of Directors as Candel advances toward Biologics License Application submission and commercial development

NEEDHAM, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Maha Radhakrishnan, M.D., to the Companys Board of Directors (Board) effective June 4, 2025.

We are delighted to welcome Maha as a new member of Candels Board,... More